Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early

Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.